New Zealand markets open in 6 hours 34 minutes

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
17.38-0.23 (-1.33%)
At close: 11:58AM EST
Full screen
Trade prices are not sourced from all markets
Previous close17.61
Open17.38
Bid0.00 x 0
Ask0.00 x 0
Day's range17.38 - 17.38
52-week range17.38 - 31.05
Volume2,044
Avg. volume2,917
Market cap10.153B
Beta (5Y monthly)0.18
PE ratio (TTM)15.90
EPS (TTM)1.09
Earnings dateN/A
Forward dividend & yield0.44 (2.55%)
Ex-dividend date03 Jun 2021
1y target estN/A
  • GlobeNewswire

    GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19

    First-in-human study evaluating recombinant hyperimmunes SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody drug designed to provide passive immunity

  • GlobeNewswire

    Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer

    SAN CARLOS, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the appointment of Dr. César Cerezo M.D., Ph.D., as chief medical officer. He will be responsible for leading and providing strategic direction to the clinical development and medical teams. “Dr. Cerezo brings to Alkahest robust and broad experience bot

  • GlobeNewswire

    GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564

    --Reduced checkpoint inhibitor activity of GIGA-564 versus current anti-CTLA-4 inhibitors results in superior anti-tumor activity and lower toxicity in murine models ----Data supports advancement of GIGA-564 into the clinic for cancer indications-- SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, a